ArticleBMC pregnancy and childbirth2025
Circulating miR-486-3p as a potential biomarker for the diagnosis of gestational diabetes mellitus and the prediction of adverse pregnancy outcomes.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in Perinatal Depression: A Focus on Screening and Treatment.Journal of clinical medicine · 2026Review
- Beyond the Apnea-Hypopnea Index: Circulating Biomarkers and Device-Based Metrics for Cardiometabolic Risk Stratification in Obstructive Sleep Apnea.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGestational diabetes mellitus (GDM) seriously endangers the health of pregnant women and their offspring. Early prediction and diagnosis allow timely treatment of GDM, preventing adverse pregnancy outcomes and related diseases. This research aims to explore the predictive significance of miR-486-3p expression levels in diagnosing GDM in early pregnancy.
methodsA retrospective study was conducted by enrolling 103 subjects with GDM and 98 healthy subjects. qRT-PCR was used to analyze the expression level of miR-486-3p. The chi-square test and t-test were used to evaluate the differences in miR-486-3p expression levels between the GDM and control groups. The predictive value of miR-486-3p in early diagnosis of GDM was analyzed by receiver operating characteristic (ROC). Potential indicators that may lead to adverse pregnancy outcomes in patients with GDM were predicted by multivariate logistic regression analysis.
resultsDownregulation of miR-486-3p expression level was observed in the GDM group compared with healthy individuals. The predictive value of miR-486-3p for early diagnosis of GDM was indicated by the ROC curve. The expression level of miR-486-3p in the GDM group was negatively correlated with glycated hemoglobin (HbA1c), fasting blood glucose (FBG), homeostasis model-insulin resistance index (HOMA-IR), and leptin (LEP). Multivariate logistic regression analysis suggested that miR-486-3p, HbA1c, HOMA-IR, and FBG could be regarded as adverse pregnancy outcome risk factors in GDM subjects.
conclusionmiR-486-3p showed a clinical predictive value for GDM in early pregnancy. miR-486-3p, HbA1c, HOMA-IR, and FBG indicators can be considered adverse pregnancy outcome risk factors in GDM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.